

Vaccibody AS initiates research in infectious diseases and hires Gunnstein Norheim, former Vaccine Science Director at CEPI, to lead initiative

- *Vaccibody expands the utilization of its technology platform into the area of infectious diseases in order to explore opportunities in this field of significant unmet medical needs*
- *Dr. Gunnstein Norheim, former Director of Vaccine Science at Coalition for Epidemic Preparedness Innovations (CEPI), is appointed to lay out the strategy and lead Vaccibody's research initiative within infectious diseases*

Oslo, Norway, April 1st, 2020 – Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, announces it will expand its activities into the infectious disease area. The Company appoints Dr. Gunnstein Norheim to head its activities in this field.

Vaccibody has, based on its unique technology platform, already laid the groundwork by generating early pre-clinical proof-of-concept within a range of infectious disease targets. In addition, the rapid, specific and strong immune responses and early clinical efficacy shown within cancer has further given valuable insight into its versatility and excellent immune response and safety profile. The infectious disease area is a large and growing commercial market with a significant unmet medical need across many indications. The broad potential of the Vaccibody platform combined with the promising data generated so far, and the attractive opportunity space within infectious diseases, has led the Company to decide to further explore the potential of this new strategic pillar.

Dr. Gunnstein Norheim will lead Vaccibody's new initiative within infectious diseases and develop the relevant research and development strategy.

"I am excited to bring Gunnstein Norheim on board as Director Infectious Diseases. With the positive clinical data from VB10.16 and VB10.NEO, we are now ready to explore the broader potential of the platform. His deep knowledge and comprehensive experience will help Vaccibody to efficiently explore and prioritize its opportunities in the infectious disease area. This area continues to be tremendously relevant, in particular in the light of the current COVID-19 pandemic. We believe that Vaccibody's technology and experience position us

well to pursue development projects within infectious diseases. With Gunnstein on board, we are eager to speed up our efforts in this area”, says President & CSO Agnete B. Fredriksen.

Gunnstein Norheim continues, “Vaccibody has a strong and versatile immunotherapy platform and a great R&D team. I am excited to join Vaccibody and look very much forward to applying my experience as well as my network to explore how the potential of the Vaccibody platform may be maximized to successfully address the public health burden of infectious diseases.”

Gunnstein Norheim will start in his new role at Vaccibody on April 1st, 2020 and will report to President & CSO Agnete B. Fredriksen.

About Dr. Gunnstein Norheim

Gunnstein Norheim holds a Ph.D. and a Master’s Degree (Cand. Pharm.) from the University of Oslo, Norway. He has extensive experience in coordinating vaccine science- and early development programs. Gunnstein has worked as a researcher in the Oxford Vaccine Group, served as a consultant to the WHO and been engaged in molecular epidemiology studies for tuberculosis, and preclinical and clinical vaccine development for meningococcal disease and Ebola with the Norwegian Institute of Public Health. In 2017, he was awarded the “Pharmacist of the year” award by the Norwegian Association of Pharmacists (NFF) for his efforts in the Phase III “Ebola ça suffit” ring vaccination trial in West Africa. He was a member of the Study Steering Group for the Ebola ring vaccination trial, and a part of the international WHO-led core team preparing the study protocol, ethical and regulatory submissions, planning logistical implementation and planning of community engagement.

During Gunnstein Norheim’s time at the Coalition for Epidemic Preparedness Innovations (CEPI), he was instrumental in establishing and developing the organization from its beginning in 2016 and to a permanent international organization. He was responsible for the scientific coordination with the CEPI Scientific Advisory Committee (SAC) which led to CEPI’s investment focus on vaccine development for WHO’s priority pathogens. Gunnstein Norheim was responsible for and for shaping CEPI’s concept on partnering with vaccine technology platform providers to test and establish capacities for responding to Disease X epidemics. As CEPI’s Director of Vaccine Science, he built up a team specializing in Strategic Science, Epidemiology and Preclinical Immunology which initiated CEPI’s investment portfolio within epidemiology, diagnostics, biological standardization and animal models; areas critical to facilitate product development, regulatory approval and future access.

About Vaccibody

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The Company is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. Further, the Company focuses its research on infectious diseases.

Vaccibody is developing cutting-edge, targeted DNA vaccines for clinical use, based on a deep understanding of immunological principles. Vaccibody's vaccines specifically target Antigen Presenting Cells (APC), which are essential for inducing rapid, strong and specific immune responses and elicit efficacious clinical responses. By intelligent design, Vaccibody's vaccines can be tailored to induce the desired immune response profile correlating with protection for each specific disease with any given antigen. Hence, the Vaccibody vaccine platform has the potential to address many disease areas with a high unmet medical need such as cancer and infectious diseases. In addition, Vaccibody has collaborations with Roche and Nektar Therapeutics.

Vaccibody's lead product candidates are VB10.NEO, a personalized therapeutic cancer neoantigen vaccine currently being evaluated in a Phase I/IIa clinical trial, and VB10.16, a therapeutic cancer vaccine against HPV16-related cancers that is currently being tested in a Phase II clinical trial.

Vaccibody's shares are traded on NOTC, a marketplace for unlisted shares managed by NOTC AS, which is owned 100% by Oslo Børs ASA, the Oslo Stock Exchange.

Further information about the Company may be found at <http://www.vaccibody.com>

Contact:

CEO Michael Engsig

Vaccibody AS

Cell: +45 6173 1509

mengsig@vaccibody.com

Vaccibody AS

Oslo Research Park

Gaustadalléen 21

0349 Oslo, Norway